Cost effectiveness of inhaled steroid withdrawal in outpatients with chronic obstructive pulmonary disease

Thorax

Volumn 61, Issue 1, 2006, Pages 29-33

  Van Der Palen, J ^a   Monninkhof, E ^a   Van Der Valk, P ^a   Sullivan, S D ^b   Veenstra, D L ^b  

^a MEDISCH SPECTRUM TWENTE   (Netherlands)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; FLUTICASONE PROPIONATE; PLACEBO;

ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOSTEROID THERAPY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DECISION SUPPORT SYSTEM; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG COST; DRUG WITHDRAWAL; FOLLOW UP; FORCED EXPIRATORY VOLUME; HOSPITAL ADMISSION; HUMAN; MONTE CARLO METHOD; OUTPATIENT; PRIORITY JOURNAL; PROBABILITY; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY ANALYSIS; SPIROMETRY; SYMPTOM;

ADMINISTRATION, INHALATION; ANDROSTADIENES; BRONCHODILATOR AGENTS; COST-BENEFIT ANALYSIS; DOUBLE-BLIND METHOD; HUMANS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RECURRENCE; WITHHOLDING TREATMENT;

EID: 30844445614     PISSN: 00406376     EISSN: None     Source Type: Journal    
DOI: 10.1136/thx.2005.044578     Document Type: Article

References (19)

1. Lipworth BJ. Systemic adverse effects of inhaled corticosteroid therapy: a systematic review and meta-analysis. Arch Intern Med 1999;159:941-55.
2. Calverley PM. Inhaled corticosteroids are beneficial in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000;161:341-2.
3. Barnes PJ. Chronic obstructive pulmonary disease. N Engl J Med 2000;343:269-80.
4. Barnes PJ. Inhaled corticosteroids are not beneficial in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000;161:342-4.
5. Keatings VM, Jatakanon A, Worsdell YM, et al. Effects of inhaled and oral glucocorticoids on inflammatory indices in asthma and COPD. Am J Respir Crit Care Med 1997;155:542-8.
6. 1 in patients with chronic obstructive pulmonary disease. A meta-analysis. Ann Intern Med 2003;138:969-73.
7. Sin DD, McAlister FA, Man SF, et al Contemporary management of chronic obstructive pulmonary disease: scientific review. JAMA 2003;290:2301-12.
8. Pauwels RA, Buist AS, Calverley PM, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med 2001;163:1256-76.
9. Jarad NA, Wedzicha JA, Burge PS, et al. An observational study of inhaled corticosteroid withdrawal in stable chronic obstructive pulmonary disease. ISOLDE Study Group. Respir Med 1999;93:161-6.
10. O'Brien A, Russo-Magno P, Karki A, et al. Effects of withdrawal of inhaled steroids in men with severe irreversible airflow obstruction. Am J Respir Crit Care Med 2001;164:365-71.
11. van der Valk PD, Monninkhof E, Van der Palen J, et al. Effect of discontinuation of inhaled corticosteroids in patients with chronic obstructive pulmonary disease: the COPE study. Am J Respir Crit Care Med 2002;166:1358-63.
12. Wouters EF, Postma DS, Fokkens B, et al. Withdrawal of fluticasone propionate from combined salmeterol/fiuticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trial. Thorax 2005;60:480-7.
13. Weinstein MC, Siegel JE, Gold MR, et al. Recommendations of the Panel on Cost-Effectiveness in Health and Medicine. JAMA 1996;276:1253-8.
14. Siegel JE, Weinstein MC, Russell LB, et al. Recommendations for reporting cost-effectiveness analyses. Panel on Cost-Effectiveness in Health and Medicine. JAMA 1996;276:1339-41.
15. Russell LB, Gold MR, Siegel JE, et al. The role of cost-effectiveness analysis in health and medicine. Panel on Cost-Effectiveness in Health and Medicine. JAMA 1996;276:1172-7.
16. Doubilet P, Begg CB, Weinstein MC, et al. Probabilistic sensitivity analysis using Monte Carlo simulation. A practical approach. Med Decis Making 1985;5:157-77.
17. Oostenbrink JB, Koopmanschap MA, Rutten FF. Handleiding voor Kostenonderzoek; methoden en richtlijnprijzen voor economische evaluatie in de gezondheidszorg. Amstelveen: College voor Zorgverzekeringen, 2000.
18. Tariefboek Mediseh Specialisten. Euroboek per 1 April 2002. Utrecht: College Tarieven Gezondheidszorg (CTG), 2002.
19. Oostenbrink JB, Koopmanschap MA, Rutten FF. Standardisation of costs: the Dutch Manual for Costing in economic evaluations. Pharmacoeconomics 2002;20:443-54.